Isoliquiritigenin inhibits TNF-α-induced release of high-mobility group box 1 through activation of HDAC in human intestinal epithelial HT-29 cells.

@article{Chi2017IsoliquiritigeninIT,
  title={Isoliquiritigenin inhibits TNF-α-induced release of high-mobility group box 1 through activation of HDAC in human intestinal epithelial HT-29 cells.},
  author={Jin-Hua Chi and Geom Seog Seo and Jae Hee Cheon and Sung Hee Lee},
  journal={European journal of pharmacology},
  year={2017},
  volume={796},
  pages={101-109}
}
The suppression of pro-inflammatory cytokine-induced inflammation responses is an attractive pharmacological target for the development of therapeutic strategies for inflammatory bowel disease (IBD). In the present study, we evaluated the anti-inflammatory properties of flavonoid isoliquiritigenin (ISL) in intestinal epithelial cells and determined its mechanism of action. ISL suppressed the expression of inflammatory molecules, including IL-8, IL-1β and COX-2, in TNF-α-stimulated HT-29 cells… CONTINUE READING

References

Publications referenced by this paper.
Showing 1-10 of 28 references

Cytokines in inflammatory bowel disease

Nature Reviews Immunology • 2014
View 2 Excerpts

Inflammatory bowel disease and thromboembolism.

World journal of gastroenterology • 2014
View 1 Excerpt

Similar Papers

Loading similar papers…